- Stocks
- Healthcare
- NASDAQ: ATNX

Price (delayed)

$3.56

Market cap

$389.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.59

Enterprise value

$454.13M

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment

ATNX's equity is up by 33% year-on-year and by 17% since the previous quarter

The quick ratio has contracted by 36% from the previous quarter but it has grown by 8% YoY

ATNX's net income is down by 25% year-on-year but it is up by 4.1% since the previous quarter

Athenex's debt has increased by 49% YoY

The gross profit has declined by 25% year-on-year and by 11% since the previous quarter

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: http://www.athenex.com

What are the main financial stats of ATNX

Market
Valuations
Earnings

Shares outstanding

109.31M

Market cap

$389.14M

Enterprise value

$454.13M

Price to earnings (P/E)

N/A

Price to book (P/B)

1.8

Price to sales (P/S)

3.06

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

3.78

Revenue

$120.23M

EBIT

-$136.83M

EBITDA

-$131.99M

Free cash flow

-$149.41M

Per share
Balance sheet
Liquidity

EPS

-$1.59

Free cash flow per share

-$1.45

Book value per share

$1.98

Revenue per share

$1.16

TBVPS

$2.58

Total assets

$408.96M

Total liabilities

$239.08M

Debt

$158.43M

Equity

$185.2M

Working capital

$150.17M

Debt to equity

0.86

Current ratio

3.39

Quick ratio

2.68

Net debt/EBITDA

-0.49

Margins
Efficiency
Dividend

EBITDA margin

-109.8%

Gross margin

34.4%

Net margin

-121.1%

Operating margin

-113.5%

Return on assets

-37.5%

Return on equity

-77.8%

Return on invested capital

-44.5%

Return on capital employed

-39.5%

Return on sales

-113.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Athenex stock price performed over time

Intraday

5.01%

1 week

2.01%

1 month

9.2%

1 year

-72.74%

YTD

-67.81%

QTD

-22.94%

How have Athenex's revenue and profit performed over time

Revenue

$120.23M

Gross profit

$41.39M

Operating income

-$136.48M

Net income

-$145.62M

Gross margin

34.4%

Net margin

-121.1%

The operating margin has dropped by 55% year-on-year and by 22% since the previous quarter

Athenex's net margin has decreased by 47% YoY and by 10% from the previous quarter

The operating income has contracted by 33% YoY and by 6% from the previous quarter

The gross profit has declined by 25% year-on-year and by 11% since the previous quarter

What is Athenex's growth rate over time

What is Athenex stock price valuation

P/E

N/A

P/B

1.8

P/S

3.06

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

3.78

The EPS has grown by 10% from the previous quarter but it has contracted by 10% YoY

The P/B is 72% lower than the 5-year quarterly average of 6.5 and 51% lower than the last 4 quarters average of 3.7

ATNX's equity is up by 33% year-on-year and by 17% since the previous quarter

The stock's P/S is 77% below its 5-year quarterly average of 13.2 and 39% below its last 4 quarters average of 5.0

The revenue has decreased by 15% YoY and by 13% from the previous quarter

How efficient is Athenex business performance

The ROS has plunged by 50% YoY and by 16% from the previous quarter

ATNX's return on invested capital is up by 38% year-on-year and by 7% since the previous quarter

ATNX's ROA is up by 11% QoQ and by 3.8% YoY

Athenex's return on equity has increased by 10% QoQ but it has decreased by 8% YoY

What is ATNX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ATNX.

How did Athenex financials performed over time

The total assets is 71% more than the total liabilities

The total liabilities is up by 39% year-on-year and by 16% since the previous quarter

The total assets has increased by 37% YoY and by 17% from the previous quarter

Athenex's debt is 14% less than its equity

Athenex's debt has increased by 49% YoY

ATNX's equity is up by 33% year-on-year and by 17% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.